[New York] – EpiVax Oncology, Inc, today announced that it has scheduled a company presentation at Biotech Showcase™ 2020, to be held January 13–15, during the most important week in healthcare at the Hilton San Francisco Union Square.
Gad Berdugo, CEO will present at Biotech Showcase as follows:
Date: Monday, January 13, 2020
Time: 9:30 A.M. (PST)
Room: Franciscan D (Ballroom Level)
Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA (United States)
"I am excited to present at Biotech Showcase. Looking forward to meeting you there!" said Gad Berdugo, CEO of EpiVax Oncology.
Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry's largest gatherings and busiest weeks.
“We are delighted that EpiVax Oncology will be presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is a prime occasion for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”
ABOUT BIOTECH SHOWCASE
Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather in San Francisco during this bellwether week which sets the tone for the coming year. Now in its 12th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.
ABOUT EPIVAX ONCOLOGY, INC.
EpiVax Oncology, Inc. is a privately held biotechnology company focusing on developing precision cancer immunotherapies based in New York City, NY. Incorporated in 2017, EpiVax Oncology is a spin-out of EpiVax Inc., a company founded by Dr. Annie De Groot and Mr. Bill Martin in 1998. EpiVax Oncology is leveraging EpiVax's 20 years of experience in designing commercial-grade immunoinformatic tools, to advance its personalized therapeutic cancer vaccine development program. EpiVax Oncology's personalized immunotherapy design platform, Ancer™, incorporates the world-class EpiMatrix® system and the innovative JanusMatrix™ tool, which were exclusively licensed to EpiVax Oncology by EpiVax. More information about EpiVax Oncology is available at www.epivaxoncology.com.
